|

Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)

RECRUITINGPhase 1/2Sponsored by Heartseed Inc.
Actively Recruiting
PhasePhase 1/2
SponsorHeartseed Inc.
Started2026-01-19
Est. completion2028-01-01
Eligibility
Age20 Years – 80 Years
Healthy vol.Accepted

Summary

The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.

Eligibility

Age: 20 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with resting left ventricular ejection fraction (LVEF) ≦40% based on institutional assessment on screening echocardiographic assessment
* New York Heart Association (NYHA) cardiac function classification of grade II or III at screening
* Other Criteria apply, please contact the investigator

Exclusion Criteria:

* Patients with cardiac devices such as pacemakers, implantable cardioverter defibrillators (ICDs), or cardiac resuscitation-enabled implantable cardioverter defibrillators (CRT-Ds)
* Patients with heart failure due to the primary disease hypertrophic cardiomyopathy (including the dilated phase), restrictive cardiomyopathy, amyloidosis, takotsubo cardiomyopathy, congenital heart disease, cardiac sarcoidosis, or constrictive pericarditis
* Other Criteria apply, please contact the investigator

Conditions5

Dilated Cardiomyopathy (DCM)Heart DiseaseHeart FailureIschemic Heart DiseaseIschemic Heart Failure

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.